Anthony S. Fauci, MD, director of NIAID, Robert W. Eisinger, PhD, and Carl W. Dieffenbach, PhD, published an article in the January 2019 online issue of JAMA, discussing U=U campaigns. The authors note that the U = U concept provides incentives for individuals with HIV to seek, initiate, and adhere to ART, as well as removes the feeling of self-imposed and external stigma that many people with HIV experience.
Dr. Fauci oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis and malaria as well as emerging diseases such as Ebola and Zika. Dr. Fauci has advised five Presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.
Robert W. Eisinger, PhD, serves as Special Assistant for Scientific Projects at the Division of Program Coordination, Planning, and Strategic Initiatives. Dr. Eisinger served as the Acting Director of OAR from 2015 to 2016. From 1989 to 2013, Dr. Eisinger served as Therapeutics Research Coordinator and as the Director of Scientific and Program Operations at OAR. In 2013, he served as the Director, Office of Research and Science, Office of the U.S. Global AIDS Coordinator, where he was responsible for managing three large international combination HIV prevention clinical studies.
Carl W. Dieffenbach, Ph.D., serves as Director of the Division of AIDS (DAIDS). Dr. Dieffenbach oversees a global HIV/AIDS research portfolio of more than $1 billion and a staff of more than 150 federal employees. Dr. Dieffenbach played a key role in restructuring the DAIDS-supported clinical trials research networks and has actively fostered collaboration and partnerships with other federal agencies, international research organizations, professional societies, foundations, community advocacy groups, and industry.
You can read the article here.